Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-06-07 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2023 third extraordinary shareholders' meeting of 圣湘生物科技股份有限公司. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company articles. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of voting results but a legal opinion on the meeting's procedural validity. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and declaration of shareholder meeting voting results and procedures.
2023-06-07 Chinese
圣湘生物科技股份有限公司2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's third extraordinary general meeting of shareholders held on June 7, 2023. It details the meeting attendance, voting results, and legal compliance, including lawyer witness statements. There is no financial data or report content, only the official voting results and meeting procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2023-06-07 Chinese
圣湘生物科技股份有限公司关于2022年年度权益分派实施后调整回购股份价格上限暨回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the adjustment of the upper limit price for the company's share repurchase program following the implementation of the 2022 annual dividend distribution. It details the progress of the share repurchase, including the number of shares repurchased, prices, and total funds used. The document references prior announcements and regulatory guidelines related to share repurchases. It does not contain financial statements or comprehensive financial data but focuses on the update and progress of the share buyback program. Therefore, this document fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2023-05-31 Chinese
圣湘生物科技股份有限公司2023年第三次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the "2023 Third Extraordinary General Meeting of Shareholders" of 圣湘生物科技股份有限公司. It contains detailed meeting instructions, agenda, and a specific proposal regarding the use of excess raised funds to supplement working capital. The content is focused on the meeting procedures, shareholder rights, voting methods, and the agenda items to be discussed and voted on during the meeting. There is no financial statement or detailed financial analysis present, nor is it a transcript or announcement of results. The document is a set of materials prepared for a shareholders' meeting, which fits the definition of AGM Information (AGM-R). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the actual meeting materials. Therefore, the correct classification is AGM Information (AGM-R).
2023-05-30 Chinese
圣湘生物科技股份有限公司2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the company's second extraordinary general meeting of shareholders in 2023. It details the meeting date, attendance, voting results on specific proposals, and legal compliance statements. There is no indication of it being a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting results declaration for an annual general meeting but rather an extraordinary shareholders meeting resolution announcement. The content focuses on the meeting proceedings and voting outcomes, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and contains detailed voting results, confirming it is not merely an announcement of a report but the actual voting results disclosure. Therefore, the appropriate classification is DVA with high confidence.
2023-05-24 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legitimacy and legality of the procedures, attendance, and voting results of a company's 2023 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it an announcement of a report publication. It is a legal opinion related to a shareholders' meeting, specifically focusing on the voting results and procedural legality. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3371 characters, which is relatively short but contains detailed voting results and legal opinion on the meeting's validity, not just a brief announcement or notice. Therefore, the best classification is DVA with high confidence.
2023-05-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.